BMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Halozyme Therapeutics (HALO) PT Raised to $22 at JPMorganFebruary 21, 2018 7:24 AM Halozyme Therapeutics (HALO) PT Raised to $24 at Deutsche BankFebruary 21, 2018 6:55 AM Halozyme Therapeutics (HALO) PT Raised to $21 at Canaccord GenuityFebruary 21, 2018 5:12 AM Halozyme Therapeutics (HALO) PT Raised to $21 at JMP SecuritiesFebruary 21, 2018 4:34 AM Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates OutlookFebruary 20, 2018 4:07 PM Halozyme Reports Fourth Quarter And Full-Year 2017 ResultsFebruary 20, 2018 4:05 PM